WOHLFAHRT, Gerd,RUMMAKKO, Petteri,PASSINIEMI, Mikko,PIETIKÄINEN, Pekka,TIAINEN, Eija,DIN BELLE, David,MÄKELÄ, Mikko,VAISMAA, Matti
申请号：
CL2019001728
公开号：
CL2019001728A1
申请日:
2019.06.20
申请国别(地区):
CL
年份:
2019
代理人:
摘要：
The compounds of F amp, oacute and rmula (I) are described as follows:Among them, R1, R2, R3, R4, R5, R23, R24, l, a and B are R1, R2, R3, R4, R5, R23, R24, l, a and B； oacute； n 1, or sales Pharmaceutical amp； eacute； defined by ILO and provincial authorities. The F amp compound； oacute； rmula (I) has the function of cytochrome inhibitor P450 monooxygenation 11A1 (CYP11A1). The compounds are amp； uacute； as drugs for the treatment of steroid receptors, especially Andr amp； oacute； genes, diseases and accessory diseases, such as NCER； oacute； Stata. lt； / P gt of C amp； Aacute； PR amp；<；p>；SE DESCRIBEN COMPUESTOS DE LA FÓ；RMULA (I), EN DONDE R1, R2, R3, R4, R5, R23, R24, L, A Y B SON COMO SE DEFINE EN LA REIVINDICACIÓ；N 1, O SALES FARMACÉ；UTICAMENTE ACEPTABLES DE LOS MISMOS. LOS COMPUESTOS DE LA FÓ；RMULA (I) POSEEN UTILIDAD COMO INHIBIDORES CITOCROMO P450 MONOOXIGENASA 11A1 (CYP11A1). LOS COMPUESTOS SON Ú；TILES COMO MEDICAMENTOS EN EL TRATAMIENTO DE RECEPTOR DE ESTEROIDE, PARTICULARMENTE RECEPTOR DE ANDRÓ；GENO, ENFERMEDADES Y AFECCIONES DEPENDIENTES, TAL COMO CÁ；NCER DE PRÓ；STATA.<；/p>；
